Cutaneous soft tissue sarcomas: survival-related factors.


Journal

Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 30 08 2020
accepted: 30 06 2021
revised: 12 06 2021
pubmed: 18 7 2021
medline: 27 7 2022
entrez: 17 7 2021
Statut: ppublish

Résumé

Cutaneous sarcomas are a heterogeneous group of rare mesenchymal neoplasms representing less than 1% of malignant tumors. Histology report remains the cornerstone for the diagnosis of these tumors. The most important clinicopathologic parameters related to prognosis include larger tumor size, high mitotic index, head and neck location, p53 mutations, depth of infiltration and histological grade, vascular and perineural invasion as well as the surgical margins status. Applying advanced biopsy techniques might offer more precise assessment of surgical margins, which constitutes a significant precondition for the management of these tumors. The management of cutaneous soft tissue sarcomas requires a multidisciplinary approach. Surgery remains the standard treatment, nonetheless adjuvant therapy may be required, consisting of radiotherapy, chemotherapy, and molecular targeted therapies to improve treatment outcomes. The role of molecular profiling in the treatment of uncontrolled disease is promising, but it may be offered to a relatively small proportion of patients and its use is still considered experimental in this setting. Due to the rarity of the disease, there is a need for knowledge and experience to be shared, pooled, organized and rationalized so that recent developments in medical science can have a major impact on the disease course. Multicenter clinical trials are needed to improve the care of patients with cutaneous sarcomas.

Identifiants

pubmed: 34272971
doi: 10.1007/s00403-021-02268-1
pii: 10.1007/s00403-021-02268-1
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

625-631

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Mentzel T (2011) Sarcomas of the skin in the elderly. Clin Dermatol 29(1):80–90
pubmed: 21146736 doi: 10.1016/j.clindermatol.2010.07.011
Wollina U, Koch A, Hansel G et al (2013) A 10-year analysis of cutaneous mesenchymal tumors (sarcomas and related entities) in a skin cancer center. Int J Dermatol 52(10):1189–1897
pubmed: 23829640
Maire G, Fraitag S, Galmiche L, Keslair F et al (2007) A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol 143(2):203–210
pubmed: 17310000 doi: 10.1001/archderm.143.2.203
Edelweiss M, Malpica A (2010) Dermatofibrosarcoma protuberans of the vulva: a clinicopathologic and immunohistochemical study of 13 cases. Am J Surg Pathol 34(3):393–400
pubmed: 20139758 doi: 10.1097/PAS.0b013e3181cf7fc1
Bowne WB, Antonescu CR, Leung DHY, Katz SC et al (2000) Dermatofibrosarcoma protuberans. A clinicopathologic analysis of patients treated and followed at a single institution. Cancer 88:2711–2720
pubmed: 10870053 doi: 10.1002/1097-0142(20000615)88:12<2711::AID-CNCR9>3.0.CO;2-M
Gloster HM Jr, Harris KR, Roenigk RK (1996) A comparison between Mohs micrographic surgery and a wide surgical excision for the treatment of dermatofibrosarcoma protuberans. J Am Acad Dermatol 35:82–87
pubmed: 8682970 doi: 10.1016/S0190-9622(96)90597-6
Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA et al (2013) Dermatofibrosarcomaprotuberans: a comprehensive review and update on diagnosis and management. Semin Diagn Pathol 30(1):13–28
pubmed: 23327727 doi: 10.1053/j.semdp.2012.01.002
Guillen DR, Cockerell CJ (2001) Cutaneous and subcutaneous sarcomas. Clin Dermatol 19:262–268
pubmed: 11479038 doi: 10.1016/S0738-081X(01)00177-8
Stranahan D, Cherpelis BS, Glass LF, Ladd S et al (2009) Immunohistochemical stains in Mohs surgery: a review. DermatolSurg 35:1023–1034
Haycox CL, Odland PB, Olbricht SM, Piepkorn M (1997) Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment. J Am Acad Dermatol 37:438–444
pubmed: 9308560 doi: 10.1016/S0190-9622(97)70146-4
Lemm D, Mügge LO, Mentzel T, Höffken K (2009) Current treatment options in dermatofibrosarcomaprotuberans. J Cancer Res Clin Oncol 135:653–665
pubmed: 19205737 doi: 10.1007/s00432-009-0550-3
Takahira T, Oda Y, Tamiya S, Yamamoto H et al (2004) Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcomaprotuberans. Hum Pathol 35:240–245
pubmed: 14991543 doi: 10.1016/j.humpath.2003.09.016
Deneve JL, Messina JL, Bui MM, Marzban SS et al (2013) Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection. Cancer Control 20(4):307–312
pubmed: 24077407 doi: 10.1177/107327481302000408
Winchester DS, Hocker TL, Brewer JD et al (2014) Leiomyosarcoma of the skin: clinical, histopathologic, and prognostic factors that influence outcomes. J Am AcadDermatol 71(5):919–925
doi: 10.1016/j.jaad.2014.07.020
Hollmig ST, Sachdev R, Cockerell CJ, Posten W et al (2012) Spindle cell neoplasms encountered in dermatologic surgery: a review. Dermatol Surg 38(6):825–850
pubmed: 22268379 doi: 10.1111/j.1524-4725.2012.02296.x
Beer TW, Drury P, Heenan PJ (2010) Atypical fibroxanthoma: a histological and immunohistochemical review of 171 cases. Am J Dermatopathol 32:533–540
pubmed: 20526171 doi: 10.1097/DAD.0b013e3181c80b97
Luzar B, Calonje E (2010) Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol 37:301–309
pubmed: 19807823 doi: 10.1111/j.1600-0560.2009.01425.x
Evans HL, Smith JL (1980) Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: ac comparative study of 38 cases. Cancer 45:2687–2697
pubmed: 7379002 doi: 10.1002/1097-0142(19800515)45:10<2687::AID-CNCR2820451034>3.0.CO;2-R
Mathew RA, Schlauder SM, Calder KB, Morgan MB (2008) CD117 immunoreactivity in atypical fibroxanthoma. Am J Dermatopathol 30:34–36
pubmed: 18212542 doi: 10.1097/DAD.0b013e31815b8ed5
Volpicelli ER, Fletcher CD (2012) Desmin and CD34 positivity in cellular fibrous histiocytoma: an immunohistochemical analysis of 100 cases. J Cutan Pathol 39(8):747–752
pubmed: 22775584 doi: 10.1111/j.1600-0560.2012.01944.x
Rouhani P, Fletcher CDM, Devesa SS, Toro JR (2008) Cutaneous soft tissue sarcoma incidence patterns in the US. An analysis of 12,114 cases. Cancer 113:616–627
pubmed: 18618615 doi: 10.1002/cncr.23571
Fields JP, Helwig EB (1981) Leiomyosarcoma of the skin and subcutaneous tissue. Cancer 47:156–169
pubmed: 7459804 doi: 10.1002/1097-0142(19810101)47:1<156::AID-CNCR2820470127>3.0.CO;2-#
Massi D, Beltrami G, Mela MM, Pertici M et al (2004) Prognosticfactors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases. Eur J Surg Oncol 30:565–572
pubmed: 15135488 doi: 10.1016/j.ejso.2004.03.002
Lang RG Jr (2008) Textbook of Dermatologic Surgery. Malignant tumors of the dermis and subcutaneous tissue. Padova: Piccin Nuova Libraria. 435–70
Abou-Jaoude M, El Ali M (2009) Malignant fibrous histiocytoma: a case report and literature review. Int Surg 94:196–200
pubmed: 20187510
Anderson CE, Al-Nafussi A (2009) Spindle cell lesions of the head and neck: an overview and diagnostic approach. Diagn Histopathol 15:264–272
doi: 10.1016/j.mpdhp.2009.02.009
Peiper M, Zurakowski D, Knoefel WT, Izbicki JR (2004) Malignant fibrous histiocytoma of the extremities and trunk: an institutional review. Surgery 135:59–66
pubmed: 14694301 doi: 10.1016/S0039-6060(03)00325-8
Dittmer DP, Damania B (2013) Kaposi sarcoma associated herpesvirus pathogenesis (KSHV)—an update. Curr Opin Virol 3(3):238–244
pubmed: 23769237 pmcid: 3716290 doi: 10.1016/j.coviro.2013.05.012
Parkin DM (2006) The global health burden of infection- associated cancers in the year 2002. Int J Cancer 118:3030–3044
pubmed: 16404738 doi: 10.1002/ijc.21731
Cassarino DS, DeRienzo DP, Barr RJ (2006) Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part Two J Cutan Pathol 33:261–279
pubmed: 16630176 doi: 10.1111/j.0303-6987.2006.00516.x
Salmon PJM, Hussain W, Geisse JK, Grekin RC et al (2011) Sclerosing squamous cell carcinoma of the skin, an underemphasized locally aggressive variant: a 20-year experience. Dermatol Surg 37:664–670
pubmed: 21269350 doi: 10.1111/j.1524-4725.2010.01850.x
Dotto JE, Glusac EJ (2006) P63 is a useful marker for cutaneous spindle cell squamous cell carcinoma. J CutanPathol 33:413–417
Nguyen HQ, Magaret AS, Kitahata MM, VanRompaey SE et al (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22(8):937–945
pubmed: 18453853 doi: 10.1097/QAD.0b013e3282ff6275
Buehler D, Rice SR, Moody JS, Rush P et al (2014) Angiosarcoma outcomes and prognostic factors, a 25-year single institution experience. Am J Clin Oncol 37:473–479
pubmed: 23428947 pmcid: 3664266 doi: 10.1097/COC.0b013e31827e4e7b
Cuccia F, Figlia V, Palmeri A, Verderame F et al (2017) Helical tomotherapy® is a safe and feasible technique for total scalp irradiation. Rare Tumors 9(1):6942
pubmed: 28435647 pmcid: 5379234 doi: 10.4081/rt.2017.6942
Mentzel T, Schildhaus HU, Palmedo G, Büttner R et al (2012) Post-radiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicpathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 25(1):75–85
pubmed: 21909081 doi: 10.1038/modpathol.2011.134
Annest NM, Grekin SJ, Stone MS, Messingham MJ (2007) Cutaneous leiomyosarcoma: a tumor of the head and neck. Dermatol Surg 33:528–533
Bernstein SB, Roenigk RK (1996) Leiomyosarcoma of the skin. Dermatol Surg 22:631–635
pubmed: 8680785
Cook TF, Fosko SW (1998) Unusual cutaneous malignancies. Semin Cutan Med Surg 17:114–132
pubmed: 9669605 doi: 10.1016/S1085-5629(98)80005-9
Meis-Kindblom JM, Kindblom LG (1998) Angiosarcoma of soft tissue: a study of 80 cases. Am J SurgPathol 22:683–697
doi: 10.1097/00000478-199806000-00005
Wollina U, Hansel G, Schönlebe J, Averbeck M et al (2011) Cutaneous angiosarcoma is a rare aggressive malignant vascular tumour of the skin. J Eur Acad Dermatol Venereol 25:964–968
pubmed: 21108661 doi: 10.1111/j.1468-3083.2010.03905.x
Mobini N (2009) Cutaneous epithelioid angiosarcoma: a neoplasm with potential pitfalls in diagnosis. J Cutan Pathol 36:362–369
pubmed: 19220634 doi: 10.1111/j.1600-0560.2008.01052.x
Foote MC, Burmeister B, Burmeister E, Bayley G et al (2008) Desmoplastic melanoma: the role of radiotherapy in improving local control. ANZ J Surg 78:273–276
pubmed: 18366400 doi: 10.1111/j.1445-2197.2008.04436.x
Sobanko JF, Meijer L, Nigra TP (2009) Epithelioid sarcoma: a review and update. J Clin Aesthet Dermatol 2(5):49–54
pubmed: 20729965 pmcid: 2924131
Mark RJ, Poen JC, Tran LM, Fu YS et al (1996) Angiosarcoma. A report of 67 patients and a review of the literature. Cancer 77(11):2400–2406
pubmed: 8635113 doi: 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z
Pawlik TM, Paulino AF, McGinn CJ, Baker LH et al (2003) Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer 98:1716–1726
pubmed: 14534889 doi: 10.1002/cncr.11667
Miller K, Goodlad JR, Brenn T (2012) Pleomorphic dermal sarcoma: adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol 36(9):1317–1326
pubmed: 22510760 doi: 10.1097/PAS.0b013e31825359e1
Lang JE, Dodd L, Martinez S, Brigman BE (2006) Case reports: acralmyxoinflammatory fibroblastic sarcoma: a report of five cases and literature review. Clin Orthop Relat Res 445:254–260
pubmed: 16446594 doi: 10.1097/01.blo.0000201158.67443.a2
Patt JC, Haines N (2016) Soft tissue sarcomas in skin: presentations and management. Semin Oncol 43(3):413–418
pubmed: 27178697 doi: 10.1053/j.seminoncol.2016.02.026
Choi JH, Ro JY (2018) Cutaneous spindle cell neoplasms: pattern-based diagnostic approach. Arch Pathol Lab Med 142(8):958–972
pubmed: 30040457 doi: 10.5858/arpa.2018-0112-RA
Welsch K, Breuninger H, Metzler G, Sickinger F et al (2018) Patterns of infiltration and local recurrences of various types of cutaneous sarcomasfollowing three-dimensional histology. J Dtsch Dermatol Ges 16(12):1434–1442
pubmed: 30537312
Tan YG, Chia CS, Loh WL, Teo MC (2016) Single-institution review of managing dermatofibrosarcoma protuberans. ANZ J Surg 86(5):372–376
pubmed: 26334110 doi: 10.1111/ans.13276
Woo KJ, Bang SI, Mun GH, Oh KS et al (2016) Long-term outcomes of surgical treatment for dermatofibrosarcoma protuberans accordingto width of gross resection margin. J Plast Reconstr Aesthet Surg 69(3):395–401
pubmed: 26646402 doi: 10.1016/j.bjps.2015.10.027
Smith-Zagone MJ, Schwartz MR (2005) Frozen section of skin specimens. Arch Pathol Lab Med 129:1536–1543
pubmed: 16329726 doi: 10.5858/2005-129-1536-FSOSS
Veronese F, Boggio P, Tiberio R, Gattoni M et al (2017) Wide local excision vs. Mohs Tübingen technique in the treatment of dermatofibrosarcomaprotuberans: a two-centre retrospective study and literature review. J Eur Acad Dermatol Venereol 31(12):2069–2076
pubmed: 28573714 doi: 10.1111/jdv.14378
Eberle FC, Kanyildiz M, Schnabl SM, Schulz C et al (2014) Three dimensional (3D) histology in daily routine: practical implementation and its evaluation. J Dtsch Dermatol Ges 12(11):1028–1035
pubmed: 25354011 doi: 10.1111/ddg.12466_suppl
Ugurel S, Kortmann RD, Mohr P, Mentzel T et al (2013) Brief S2k guidelines-Dermatofibrosarcomaprotuberans. J Dtsch Dermatol Ges 11(3):16–19
pubmed: 23734891 doi: 10.1111/ddg.12015_4
Lindner NJ, Scarborough MT, Powell GJ, Spanier S et al (1999) Revision surgery in dermatofibrosarcoma protuberans of the trunk and extremities. Eur J Surg Oncol 25:392–397
pubmed: 10419710 doi: 10.1053/ejso.1999.0663
Hamid R, Hafeez A, Darzi AM, Zaroo I et al (2013) Dermatofibrosarcoma protuberans: role of wide local excision. South Asian J Cancer 2:232–238
pubmed: 24455646 pmcid: 3889049 doi: 10.4103/2278-330x.119926
Kokkinos C, Sorkin T, Powell B (2014) To Mohs or not to Mohs. J Plast Reconstr Aesthet Surg 67(1):23–26
pubmed: 24100204 doi: 10.1016/j.bjps.2013.08.022
Meguerditchian AN, Wang J, Lema B, Kraybill WG et al (2010) Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol 33:300–303
pubmed: 19858696 doi: 10.1097/COC.0b013e3181aaca87
Loghdey MS, Varma S, Rajpara SM, Al-Rawi H et al (2014) Mohs micrographic surgery for Dermatofibrosarcomaprotuberans (DFSP): a single-centre series of 76 patients treated by frozen-section Mohs micrographic surgery with a review of the literature. J Plast Reconstr Aesthet Surg 67(10):1315–1321
pubmed: 25012249 doi: 10.1016/j.bjps.2014.05.021
Lowe GC, Onajin O, Baum CL, Otley CC et al (2017) A comparison of Mohs micrographic surgery and wide local excision for treatment of dermatofibrosarcoma Protuberanswith long-term follow-up: the mayo clinic experience. Dermatol Surg 43(1):98–106
pubmed: 27749444 doi: 10.1097/DSS.0000000000000910
Luke JJ, Keohan ML (2012) Advances in the systemic treatment of cutaneous sarcomas. SeminOncol 39(2):173–183. https://doi.org/10.1053/j.seminoncol.2012.01.004
doi: 10.1053/j.seminoncol.2012.01.004
Castle KO, Guadagnolo BA, Tsai CJ, Feig BW et al (2013) Dermatofibrosarcomaprotuberans: long-term outcomes of 53 patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 86(3):585–590
pubmed: 23628134 doi: 10.1016/j.ijrobp.2013.02.024
Sun LM, Wang CJ, Huang CC, Leung SW et al (2000) Dermatofibrosarcoma protuberans: treatment results of 35 cases. Radiother Oncol 57:175–181
pubmed: 11054521 doi: 10.1016/S0167-8140(00)00228-0
Williams N, Morris CG, Kirwan JM, Dagan R et al (2014) Radiotherapy for dermatofibrosarcomaprotuberans. Am J ClinOncol 37(5):430–432
doi: 10.1097/COC.0b013e31827dee86
Starling J 3rd, Coldiron BM (2011) Mohs micrographic surgery for the treatment of cutaneous leiomyosarcoma. J Am Acad Dermatol 64(6):1119–1122
pubmed: 21571171 doi: 10.1016/j.jaad.2010.11.051
Perez MC, Padhya TA, Messina JL, Jackson R et al (2013) Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 20(11):3391–3397
pubmed: 23835652 pmcid: 4509495 doi: 10.1245/s10434-013-3083-6
Iwata S, Yonemoto T, Araki A, Ikebe D et al (2014) Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol 110(6):707–711
pubmed: 24975462 doi: 10.1002/jso.23708
Cooper JZ, Newman SR, Scott GA, Brown MD (2005) Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases. Dermatol Surg 31(2):221–225
pubmed: 15762219 doi: 10.1097/00042728-200502000-00019
Ng A, Nishikawa H, Lander A, Grundy R (2005) Chemosensitivity in pediatric dermatofibrosarcomaprotuberans. J Pediatr Hematol Oncol 27(2):100–102
pubmed: 15701986 doi: 10.1097/01.mph.0000152861.05622.99
Thway K, Noujaim J, Jones RL, Fisher C (2016) Dermatofibrosarcomaprotuberans: pathology, genetics, and potential therapeutic strategies. Ann Diagn Pathol 25:64–71
pubmed: 27806849 doi: 10.1016/j.anndiagpath.2016.09.013
Tazzari M, Indio V, Vergani B, De Cecco L et al (2017) Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. J Invest Dermatol 137(2):484–493
pubmed: 27608549 doi: 10.1016/j.jid.2016.06.634
Miyagawa T, Kadono T, Kimura T, Saigusa R et al (2017) Pazopanibinduced a partial response in a patientwithmetastaticfibrosarcomatousdermatofibrosarcomaprotuberanswithoutgenetictranslocationsresistanttomesna, doxorubicin, ifosfamideanddacarbazinechemotherapyandgemcitabine-docetaxelchemotherapy. J Dermatol 44(3):e21–e22
pubmed: 27988943 doi: 10.1111/1346-8138.13717
Fujisawa Y, Yoshino K, Fujimura T, Nakamura Y et al (2018) Front Oncol 8:46
pubmed: 29552543 pmcid: 5840142 doi: 10.3389/fonc.2018.00046
Bower M, Palfreeman A, Alfa-Wali M, Bunker C et al (2014) British HIV association guidelines for HIV-associated malignancies 2014. HIV Med 15(2):1–92
pubmed: 24528810
Busakhala N, Kigen G, Waako P, Strother RM et al (2019) Three year survival among patients with aids-related Kaposi sarcoma treated with chemotherapy and combination antiretroviral therapy at Moi teaching and referral hospital. Kenya Infect Agent Cancer 14:24
pubmed: 31516547 doi: 10.1186/s13027-019-0242-9
Dagan R, Morris CG, Zlotecki RA, Scarborough MT et al (2005) Radiotherapy in the treatment of dermatofibrosarcomaprotuberans. Am J Clin Oncol 28(6):537–539
pubmed: 16317260 doi: 10.1097/01.coc.0000171278.69291.64

Auteurs

Areti Gkantaifi (A)

Radiotherapy Department, Theagenio Anticancer Hospital of Thessaloniki, Thessaloniki, Greece.

Alexandros Diamantis (A)

Department of General Surgery, University Hospital of Larisa, Biopolis, 415 00, Larisa, Thessaly, Greece.

Davide Mauri (D)

Department of Medical Oncology, University Hospital of Ioannina, Ioannina, Greece.

Ioanna Nixon (I)

Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, G12 0YN, UK.

Anastassios Kyriazoglou (A)

2nd Propaedeutic Department of Medicine, Attikon University Hospital, Rimini St, Chaidari, 124 62, Athens, Greece.

Ioannis Baloyiannis (I)

Department of General Surgery, University Hospital of Larisa, Biopolis, 415 00, Larisa, Thessaly, Greece.

Nikolaos Tsoukalas (N)

Oncology Clinic, 401 General Military Hospital, 115 25, Athens, Greece.

Nikolaos Charalampakis (N)

Oncology Clinic, Metaxa Cancer Hospital, Mpotasi 51, 185 37, Piraeus, Greece.

Dimitrios Schizas (D)

First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.

Francesco Cuccia (F)

Advanced Radiation Oncology Department, IRCCS SacroCuore Don Calabria, Negrar, Verona, Italy.
University of Brescia, Brescia, Italy.

Filippo Alongi (F)

Advanced Radiation Oncology Department, IRCCS SacroCuore Don Calabria, Negrar, Verona, Italy.
University of Brescia, Brescia, Italy.

Ramon Andrade de Mello (RA)

Precision Oncology and Health Economics Research Group, Division of Medical Oncology, Federal University of São Paulo (UNIFESP) and Post Graduation Program in Medicine, Nine of July University (UNINOVE), São Paulo, Brazil.
Algarve Biomedical Center, Division of Oncology, Department of Biomedical Sciences and Medicine, University of Algarve, Faro, Portugal.

George Iliadis (G)

Radiotherapy Department, Interbalkan Medical Center, Thessaloniki, Greece.

Konstantinos Kamposioras (K)

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

Michalis Mazonakis (M)

Department of Medical Physics, Faculty of Medicine, University of Crete, P.O. Box 2208, 710 03, Iraklion, Crete, Greece.

Maria Tolia (M)

Department of Radiotherapy, University Hospital/Medical School, University of Crete, Vassilika, 711 10, Crete, Greece. mariatolia@uoc.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH